CANCER AND LEUKEMIA GROUP B

该申请是CALGB的首次竞争性续签 北卡罗来纳大学提交的院校赠款 教堂山(UNC-CH)及其附属公司。北卡罗来纳大学-CH一直是 CALGB自1986年以来，目前至少跻身集团前三分之一 以任何标准衡量的机构，但仅获得NCI 通过周期外审查和类型5提供的机构支持 在过去的一年里重新分配。之前的评论都称赞了 以北卡罗来纳大学-CH成员为代表的卓越科学和领导力 以及我们的数据管理和质量保证。我们继续 我们的应计收入在1991年迅速扩大到近200起。而且，我们的 机构目前在集团拥有广泛的领导层参与 几乎是每一个委员会，并且是少数族裔CCOP的研究基地。 我们已将第一阶段、第二阶段、第三阶段和配套研究的应计项目增加到 远高于其他优秀院校平均水平的水平 在集团里。其次，我们增加了拥有以下内容的主要分支机构 在保持卓越数据质量的同时，实现了我们1991年应计收入的50% 控制并建立了严格的内部审计和质量 保证程序。在1992年，我们将增加几个新的分支机构 未来增加50-100个案件的能力(包括 少数族裔案件的比例很高)，而我们目前的基线是200起。 第三，我们在本集团的领导努力也在继续扩大。 我们现在有两个委员会主席，三个 委员会副主席，16名委员会核心成员，2名执行 委员会成员，20多名礼宾首席研究员或联合研究员- 调查人员和三名董事会成员。此外, 联合国儿童基金会通过CALGB所做的努力有助于促成 向我们的附属公司MCV的Chris Desch颁发少数CCOP奖，并为 他在弗吉尼亚州南部的少数民族CCOP计划，该计划使用北卡罗来纳大学CH作为其 研究基地。我们对所有CALGB研究的总体少数应计利润仍然存在 是全国平均水平的五倍，为25%，我们女性的应收率为58% 相比之下，集团的平均水平为53%。我们计划继续提供直航服务 首先，维持一个积极的参考实验室 在涉及白血病、骨髓异常增生症、乳腺和 结直肠研究。我们进一步扩大了群体科学的范围， 增加了骨髓发育不良、急性髓细胞白血病和乳腺癌的配对研究 由爱迪生·刘、戴尔·桑德勒、罗伯特·桑德勒和保罗·戈德利设计， 其中一些拥有独立的资金。我们的前任和新任成员 机构继续扩大我们对集团科学的贡献 和行政委员会和研究(H.Ozer，执行委员会， 白血病核心，淋巴瘤核心，PET核心，生物治疗副主席，工业 关系核心；K·拉奥，细胞遗传学核心；J·泰珀，放射肿瘤学 执行委员会核心，GI副主席；Gavigan，数据审计核心， 肿瘤护理主席；D.Sandler，流行病学主席，Related 科学核心；刘E，相关科学核心；T.Shea，移植核心； 首页--期刊主要分类--期刊细介绍--期刊题录与文摘--期刊详细文摘内容 戈德利，少数派财团)。北卡罗来纳大学-CH分校将增加教员 我们在乳房和手术委员会中的承诺和集团领导地位 (J.Huth，W.Cance，M.Graham，J.Mohler)；放射疗法(S.Sailer)， 流行病学(P.Godley)、癌症预防和控制科学(R. Sandler)和Gu(P.Godley)。因此，我们相信这项申请 反映了北卡罗来纳大学-CH调查人员不断增长的关键贡献 在领导力、科学和服务方面向集团提供，并确认我们的 积极努力通过增加主要项目来增加应计利润 联营公司严格控制质量数据提交。

This application represents the first competitive renewal of the CALGB institutional grant submission from the University of North Carolina at Chapel Hill (UNC-CH) and its affiliates. UNC-CH has been a member of CALGB since 1986 and currently ranks at least in the top third of Group institutions as judged by any yardstick, but only received NCI institutional support through out-of-cycle review and Type 5 redistribution this past year. Previous reviews have praised the excellent science and leadership represented by the UNC-CH membership as well as our data management and quality assurance. We have continued our rapid accrual expansion to nearly 200 cases in 1991. Moreover, our institution now has broad leadership participation in the Group in virtually every committee and is the research base for a Minority CCOP. We have increased accrual to Phase I, II, III and companion studies to a level that is well above the average of other outstanding institutions in the Group. Secondly, we have added major affiliates that have achieved 50% of our 1991 accrual while maintaining excellent data quality control and have established rigorous internal audit and quality assurance procedures. In 1992, we will add several new affiliates with the future capacity to accrue between 50-100 additional cases (including a high proportion of minority cases) to our current baseline of 200. Third, our leadership efforts in the Group have also continued to expand. We now enjoy the distinction of having two committee chairs, three committee vice-chairs, sixteen committee core members, two Executive Committee members, more than 20 protocol principal investigators or co- investigators and three members of the Board of Directors. In addition, the efforts of UNC-CH through CALGB were instrumental in leading to the Minority CCOP award to Chris Desch of our affiliate, MCV and funding of his Minority CCOP Program in Southern Virginia, which uses UNC-CH as its research base. Our overall minority accrual to all CALGB studies remains at five times the national average at 25% and our accrual of women is 58% compared to the Group average of 53%. We plan to continue direct service to the Group by first of all maintaining an active reference laboratory in molecular epidemiology involving leukemia, myelodysplasia, breast and colorectal studies. We have further broadened Group science by the addition of companion studies in myelodysplasia, AML and breast cancer designed by Edison Liu, Dale Sandler, Robert Sandler and Paul Godley, some with independent funding. Previous and new members of our institution have continued to expand our contribution to Group scientific and administrative committees and studies (H. Ozer, Executive Committee, Leukemia Core, Lymphoma core, PET Core, Biotherapy vice-Chair, Industrial Relations Core; K. Rao, Cytogenetics Core; J. Tepper, Radiation Oncology Core, Executive Committee, GI Vice-Chair; Gavigan, Data Audit Core, Oncology Nursing Chair; D. Sandler, Epidemiology Chair, Correlative Science Core; E. Liu, Correlative Science core; T. Shea, Transplant core; J. Rosenman, Radiation Oncology core; R. Sandler, Epidemiology; P. Godley, Minority Consortia). Additional faculty at UNC-CH will expand our commitment and Group leadership in the Breast and Surgery committees (J. Huth, W. Cance, M. Graham, J. Mohler); Radiation Therapy (S. Sailer), Epidemiology (P. Godley), Cancer Prevention and Control Sciences (R. Sandler) and GU (P. Godley). We therefore believe that this application reflects the growing and crucial contribution that UNC-CH investigators provide to the Group in leadership, science and service and confirms our energetic efforts to increase accrual through the addition of major affiliates with rigorous control of quality data submission.